Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents.

Autor: Papa A; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Cursaro I; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Pozzetti L; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Contri C; Department of Translational Medicine, University of Ferrara, Ferrara, Italy., Cappello M; Department of Translational Medicine, University of Ferrara, Ferrara, Italy., Pasquini S; Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy., Carullo G; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Ramunno A; Department of Pharmacy, University of Salerno, Fisciano, Italy., Gemma S; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Varani K; Department of Translational Medicine, University of Ferrara, Ferrara, Italy., Butini S; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Campiani G; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy., Vincenzi F; Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Jazyk: angličtina
Zdroj: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2023 Dec; Vol. 356 (12), pp. e2300410. Date of Electronic Publication: 2023 Sep 26.
DOI: 10.1002/ardp.202300410
Abstrakt: Aiming to simultaneously modulate the endocannabinoid system (ECS) functions and the epigenetic machinery, we selected the fatty acid amide hydrolase (FAAH) and histone deacetylase (HDAC) enzymes as desired targets to develop potential neuroprotective multitarget-directed ligands (MTDLs), expecting to achieve an additive or synergistic therapeutic effect in oxidative stress-related conditions. We herein report the design, synthesis, and biological evaluation of the first-in-class FAAH-HDAC multitarget inhibitors. A pharmacophore merging strategy was applied, yielding 1-phenylpyrrole-based compounds 4a-j. The best-performing compounds (4c, 4f, and 4h) were tested for their neuroprotective properties in oxidative stress models, employing 1321N1 human astrocytoma cells and SHSY5 human neuronal cells. In our preliminary studies, compound 4h stood out, showing a balanced nanomolar inhibitory activity against the selected targets and outperforming the standard antioxidant N-acetylcysteine in vitro. Together with 4f, 4h was also able to protect 1321N1 cells from tert-butyl hydroperoxide or glutamate insult. Our study may provide the basis for the development of novel MTDLs targeting the ECS and epigenetic enzymes.
(© 2023 The Authors. Archiv der Pharmazie published by Wiley-VCH GmbH on behalf of Deutsche Pharmazeutische Gesellschaft.)
Databáze: MEDLINE
Externí odkaz: